Scars form as a result of the healing process of the body. The body creates tissue to repair damaged skin and fill gaps caused by an injury. Accident, burns, surgery, acne, and illness can develop scars on the body.
To close a wound quickly after an incision, skin cells multiply and synthesize the elements that surround them, such as collagen or elastin. The scar is formed as a result of the formation of new fibrous tissue. Any surgical incision results in the formation of a scar, the final appearance of which will be determined by a number of factors, including its anatomical site, operative techniques, sutures, intrinsic patient-related factors, extrinsic factors such as environmental factors.
U.S. Post-Surgical Scar Treatment Market - Impact of the Coronavirus (COVID-19) Pandemic
The number of surgeries such as open heart surgery, C-sections, appendectomy, mastectomy, or knee replacement surgery can cause scars on the body. In 2020, the COVID-19 pandemic disrupted delivery of healthcare services around the U.S., including delays in various elective surgical procedures. For instance, according to an article published in JAMA Network, Journal of the American Medical Association is a peer-reviewed medical journal, in December 2021, a cohort study of pediatric and adult patients from January 1, 2019 to January 30, 2021, undergoing surgery in the U.S. was conducted. Moreover, the study's findings revealed a 48.0% decrease in total surgical procedure volume immediately following the March 2020 recommendation to cancel elective surgical procedures. Thus, the preceding example suggests that there was a decrease in the overall number of surgical procedures performed in the U.S., which may have resulted in a decrease in the treatment of post-surgical scars on the body. Therefore, the COVID-19 impact is expected to hinder the growth of the U.S. post-surgical scar treatment market over the forecast period.
The U.S. post-surgical scar treatment market is estimated to be valued at US$ 2,680.1 Mn in 2022, and is expected to exhibit a CAGR of 10.1% over the forecast period (2022-2030).
Increasing number of surgical procedures in the U.S. is the major factor that is expected to drive growth of the U.S. post-surgical scar treatment market over the forecast period.
The increasing number of surgical procedures in the U.S. population is expected to drive growth of the U.S. post-surgical scar treatment market, over the forecast period. According to the National Center for Biotechnology Information (NCBI), 2020, the following graph shows the number of plastic surgeries carried out in the year 2017, 2018, 2019, and 2020, in the U.S.
Figure 1: Number of Plastic Surgeries in the U.S.
Increasing number of product launches by the market players is expected to drive the market growth over the forecast period
Market players are indulged in launching number of innovative products for the treatment of scars. This is expected to drive growth of the U.S. post-surgical scar treatment market, over the forecast period. For instance, on November 11, 2021, Estas Beauty, a manufacturer of skin care products, launched three products i.e., ‘Morning Massage’ cleansing oil with vitamin E & primrose; a ‘Daily Dose’ vitamin E & C cream serum; and ‘Sleep Salve’ silicone & Vitamin E mask. All the three products has silicone, which increases hydration and reduces collagen production, itching, and discomfort. The product is used for patients who undergo surgical procedures and develop scarring.
|Base Year:||2021||Market Size in 2022:||US$ 2,680.1 Mn|
|Historical Data for:||2017 to 2021||Forecast Period:||2022 to 2030|
|Forecast Period 2020 to 2030 CAGR:||10.1%||2030 Value Projection:||US$ 5,769.4 Mn|
Smith & Nephew Plc., 3M, Cardinal Health, Merz Pharma, Biodermis, Scar Heal, Inc., Mölnlycke Health Care AB, Implantech, Covalon Technologies Ltd., Bio Med Sciences, Polymer Science, Inc., and Neodyne Biosciences, Inc.
|Restraints & Challenges:||
Figure 2: U.S. Post-Surgical Scar Treatment Market Share (%) Analysis, By Product Type, 2022
U.S. Post-Surgical Scar Treatment Market – Restraints
The availability of other treatments such as laser treatment for post-surgical scars is expected to hamper growth of the U.S. post-surgical scar treatment market over the forecast period. According to the article published in the American Society of Plastic Surgeons: 2020, laser therapy is a safe and effective treatment for scars. According to the same source, dermatologists can use a laser to reduce a scar's appearance and minimize pain and itching. Laser treatment can also prevent scars from forming after surgery. Laser treatment also helps to stimulate new and healthy skin growth.
U.S. Post-Surgical Scar Treatment Market – Competitive Landscape
Major players operating in the U.S. post-surgical scar treatment market include Smith & Nephew Plc., 3M, Cardinal Health, Merz Pharma, Biodermis, Scar Heal, Inc., Mölnlycke Health Care AB, Implantech, Covalon Technologies Ltd., Bio Med Sciences, Polymer Science, Inc., and Neodyne Biosciences, Inc.
Any burn, injury, or trauma such as surgeries can cause a scar on the skin. Scarring is a natural healing process, which occurs after an injury. Its appearance and treatment depend on multiple factors such as the depth and size of the wound or the cut. It also depend upon the location of the wound, age, sex, and genes. There are various types of scars such as keloid scars, contracture scars, acne scars, and hypertrophic scars. Keloid scars are formed due to an over-aggressive healing process. They usually extend beyond their original location of the injury. Treatment of keloid scars include surgery, steroid injections, silicone sheets, and others. Hypertrophic scars are raised red scars and treatment of these scars include injection of steroids or silicone sheets.
Market players are engaged in inorganic growth activities such as acquisitions, and this is expected to drive growth of the U.S. post-surgical scar treatment market, over the forecast period. For instance, in April 2019, Merz, a company involved in aesthetics and neurotoxins, and Laboratoire HRA Pharma SAS, an innovative U.S. consumer healthcare company, entered into an agreement to acquire the asset purchase agreement, according to which HRA Pharma will acquire the U.S. rights to the Mederma brand of Merz, which includes products across the scar care, stretch marks, and skincare categories.
Moreover, in October 2019, 3M, a multinational conglomerate corporation operating in the fields of industry, worker safety, health care, and consumer goods, completed the acquisition of Acelity, Inc., a medical device company, to expand its surgical applications business, which include advanced wound care and specialty surgical applications marketed under the KCI brand (PROMOGRAN) in the developed economies such as the U.S.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.